Go To Content
:::

TFDA holds expert meeting to discuss and review UBI's application to manufacture its COVID-19 vaccine UB-612

  • Publication Data :
  • Last updated:2021-08-17
  • Count Views:25

The Taiwan Food and Drug Administration (TFDA) of the Ministry of Health and Welfare pointed out that it had invited domestic experts on August 15 to a meeting to discuss and review United BioPharma Inc.'s (UBI) application to manufacture its COVID-19 vaccine UB-612 (the UBI vaccine). Because the UBI vaccine fails to meet the two efficacy standards for granting the Emergency Use Authorization (EUA) to domestically-produced vaccines, after holding a vote on UBI's application at the meeting, experts recommended that the TFDA approval for the UBI's request for the manufacture of its COVID-19 vaccine not be granted.

~The news from Taiwan Centers for Disease Control~

Go Top \